Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Further investigation into the combined cardiotoxicity profile of ICI and FOLFOX therapies will help improve cardiovascular surveillance and management of these patients.”
Clinical trial reveals improved disease-free survival with atezolizumab plus Folfox for stage III dMMR colon cancer, indicating potential treatment advancement.
The addition of atezolizumab to mFOLFOX6 significantly improved disease-free survival among patients with stage III dMMR colon cancer. (Funded by the National Cancer Institute of the National Institutes of Health and Genentech; ATOMIC ClinicalTrials.gov number, NCT02912559.).
No takes yet. Share an insight, caveat, or question.
Sinicrope et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: